Indian Glivec case concerns raised at Novartis' AGM at Basel

P. T. Jyothi Datta Mumbai | Updated on November 20, 2017 Published on February 24, 2012


NGO shareholder tells company to drop the case

Just days away from the final hearing on a case regarding Novartis' cancer drug, Glivec, at the Supreme Court – the issue was raised by a shareholder at Novartis' annual general meeting in Basel, Switzerland.

Drop the legal case in India on Glivec, Mr Patrick Durisch with Berne Declaration, a Swiss public interest non-government organisation, urged the Novartis management.

At stake here is more than granting of a patent on Glivec – there are implications regarding access to medicines for cancer and other patients, Mr Durisch told Business Line, from Basel.

Novartis' legal challenge aims “to weaken a legitimate and invaluable public health clause of the Indian law, section 3(d), which intends to limit the multiplication of patents on trivial changes to existing medicines, a common practice by multinational pharmaceutical companies known as ‘evergreening',” he said at the AGM.

“Thanks to this safeguard, patent applications on minor modifications of existing AIDS medicines, as well as medicines to treat other diseases, have been rejected.., allowing for competition with generic equivalents upon the expiry of the patent term,” he added.

A patent allows a company to market its product for 20 years, exclusively. The Glivec patent case is a watershed event, as the final outcome will further clarify the implementation of the amended Indian Patents Acts – particularly on issues regarding the interpretation and assessment of efficacy of the medicine seeking a product patent.

Occupy Novartis

Mr Durisch's statement was on behalf of an international NGO coalition, and there were protestors outside the AGM venue, he said. On the day before the AGM, protestors participated in the “occupation of Novartis offices” in the US, he added.

The “occupy” method of international protest was against economic inequalities, and one of the more high profile protests was “Occupy Wall Street” in New York City, late last year.

Seeking clarification

Responding to the shareholder query, Novartis' Chairman, Dr Daniel Vasella, disagreed with the observation that the Supreme Court decision would lead to India no longer being able to produce generic drugs. About 95 per cent of essential medication is free from patents and the changes are only with respect to new drugs, he said.

The “deep rooted dilemma”, he added, was that intellectual property was important for innovation.

The objective of the case is not to prevent access to medicine but to find out what the law says, he said. Echoing similar thoughts, Novartis Chief Executive, Mr Joseph Jimenez, said that the ongoing case was to get clarification on the Indian patent law. Dr Vasella further offered an opportunity to dialogue with the NGOs.


Published on February 24, 2012

A letter from the Editor

Dear Readers,

The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.

Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.

In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.

We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.

But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.

I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.

A little help from you can make a huge difference to the cause of quality journalism!

Support Quality Journalism
This article is closed for comments.
Please Email the Editor
You have read 1 out of 3 free articles for this week. For full access, please subscribe and get unlimited access to all sections.